<DOC>
	<DOC>NCT00389740</DOC>
	<brief_summary>The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.</brief_summary>
	<brief_title>A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Patient is postmenopausal (or surgically menopausal) for at least 6 months Patient must be diagnosed with osteoporosis Patient has spinal anatomy suitable for DEXA of the lumbar spine Patient is receiving or has received treatment prior to randomization which might influence bone turnover Patient has a history of or evidence for metabolic bone disease (other than postmenopausal bone loss) Patient is receiving or is expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>